1.Photodynamic therapy for malignant and non-malignant diseases: clinical investigation and application.
Yong-gang QIANG ; Xiu-ping ZHANG ; Jian LI ; Zheng HUANG
Chinese Medical Journal 2006;119(10):845-857
Brain Neoplasms
;
drug therapy
;
Cardiovascular Diseases
;
drug therapy
;
Eye Diseases
;
drug therapy
;
Gastrointestinal Neoplasms
;
drug therapy
;
Head and Neck Neoplasms
;
drug therapy
;
Humans
;
Lung Neoplasms
;
drug therapy
;
Neoplasms
;
drug therapy
;
Photochemotherapy
;
Precancerous Conditions
;
drug therapy
;
Skin Diseases
;
drug therapy
;
Skin Neoplasms
;
drug therapy
;
Tooth Diseases
;
drug therapy
;
Urologic Neoplasms
;
drug therapy
2.The Hidden Culprit: A Case of Repeated Anaphylaxis to Cremophor.
Young Nam KIM ; Jun Young KIM ; Ji Won KIM ; Jin Hae KIM ; Hye In KIM ; Sehyo YUNE ; Dong Chull CHOI ; Byung Jae LEE
Allergy, Asthma & Immunology Research 2016;8(2):174-177
Drug-induced anaphylaxis is a big pitfall in patients receiving antineoplastic chemotherapy. We report a case of lung cancer patient who experienced two near-fatal anaphylactic reactions that resulted from paclitaxel and multivitamin, seperately. Recurrent severe reactions to different agents led to further investigation to which material the patient was hypersensitive. The skin prick test revealed sensitization to cremophor, which is a commonly used emulsifying agent. This case emphasizes the importance of correctly identifying the culprit drug of anaphylaxis to avoid potentially fatal reaction.
Anaphylaxis*
;
Drug Therapy
;
Humans
;
Hypersensitivity
;
Lung Neoplasms
;
Paclitaxel
;
Skin
3.A Case of Scleroderma Probably Induced by Colon Cancer or 5-FU Therapy.
Korean Journal of Dermatology 2003;41(5):663-665
Scleroderma is a chronic disease of unknown etiology, it is the sclerosis of the skin characterized by the appearance of circumscribed or diffuse, hard, smooth and ivory-colored areas that are immobile and give the appearance of hidebound skin. Progressed scleroderma can lead to develop various tumors by affecting organs. It is rarely reported that the tumor itself or systemic chemotherapy could be one of the causes of scleroderma. Up to now, the pathogenesis about scleroderma occurring from cancer itself or anticancer drugs are uncertain.
Chronic Disease
;
Colon*
;
Colonic Neoplasms*
;
Drug Therapy
;
Fluorouracil*
;
Sclerosis
;
Skin
4.Case Series of Different Onset of Skin Metastasis According to the Breast Cancer Subtypes.
Junhyeon CHO ; Yohan PARK ; Jong Chan LEE ; Woo Jin JUNG ; Soohyeon LEE
Cancer Research and Treatment 2014;46(2):194-199
We report on five cases of skin metastasis according to the breast cancer (BC) subtype. Two cases of HER2 positive BC showed only skin metastasis after immediate postoperative period and rapid clinical response to targeted therapy. Another two cases of triple negative BC showed thyroid and lung metastasis in addition to skin metastasis, and their response of cytotoxic chemotherapy was not definite. The other hormone positive BC showed skin metastasis only, with a longer, slower, less progressive pattern than other subtypes. Most cases of skin metastasis were detected at terminal stage of malignancy and were considered to have a limited survival period. However, some BC patients can survive longer if the targeted agents are effective. Therefore, physicians should provide detailed follow up of BC after curative treatment and understand the metastatic pattern of BC according to the subtype.
Breast Neoplasms*
;
Drug Therapy
;
Humans
;
Lung
;
Neoplasm Metastasis*
;
Postoperative Period
;
Skin Neoplasms
;
Skin*
;
Thyroid Gland
5.Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy.
Eun Ae PARK ; Jung Wan SEO ; Sun Wha LEE ; Hae Young CHOI ; Seung Joo LEE
Journal of Korean Medical Science 2001;16(1):127-129
Infantile hemangioendothelioma is a severe disease with a high mortality. It is characterized by multiple hemangioma affecting the skin and visceral organs. We report that high doses of methylprednisolone pulse therapy improved symptoms and signs of infantile hemangioendothelioma in a male neonate, and completely resolved the hepatic and cutaneous hemangioendothelioma on follow up.
Case Report
;
Hemangioendothelioma/drug therapy*
;
Human
;
Infant, Newborn
;
Liver Neoplasms/drug therapy*
;
Male
;
Methylprednisolone/administration & dosage*
;
Skin Neoplasms/drug therapy*
6.Clinical application of imiquimod for the treatment of infantile hemangiomas.
Gang MA ; Xiao-Xi LIN ; Cheng-Hong JIANG ; Hui CHEN ; Wei LI ; Xiao-Jie HU ; Yun-Bo JIN ; Da CHEN ; Xiao-Dong CHEN ; Xiao-Xiao YE
Chinese Journal of Plastic Surgery 2011;27(6):411-414
OBJECTIVETo explore the clinical application of imiquimod for the treatment of infantile hemangiomas (IH).
METHODS320 children with IH, including 250 superficial cases, 20 deep cases, and 50 mixed cases, were treated with 5% imiquimod cream every other day for 16 weeks. The clinical efficacy and side effects were evaluated at one year of age.
RESULTSThe total effective rates of the superficial, deep, and mixed IH were 61.2% (153/250), 10.0% (2/20) and 60.0% (30/50) respectively, showing no statistical difference between superficial and deep type (P = 0.874), but significant difference between superficial and mixed (P < 0.01), deep and mixed type (P < 0.01). 56.0% (28/50) of mixed IH showed proliferation of its deep lesions. Slight skin erythema and crusting were the most common side effects.
CONCLUSIONS5% imiquimod cream is effective and safe in superficial IH and superficial lesions of mixed IH with minimal skin reactions. The dysplasia of local tissue and systemic growth retardation are not found. It should be avoided to apply the cream to IH located around the cavities and skin fold. Imiquimod cream is a simple and convenient home-nursing medication. It can reduce care burden of family. Thus topical use of imiquimod can be considered as a good clinical indication for the treatment of superficial lesions of IH.
Aminoquinolines ; therapeutic use ; Female ; Hemangioma ; drug therapy ; Humans ; Infant ; Male ; Skin Neoplasms ; drug therapy ; Treatment Outcome
8.Clinical effect of sirolimus in treatment of blue rubber bleb nevus syndrome in children: a report of 2 cases and literature review.
Xu QUAN ; Chun-Di XU ; Ping LIU ; Qing-Qing ZHANG ; Ye CHEN ; Le WANG ; Yuan XIAO
Chinese Journal of Contemporary Pediatrics 2020;22(9):1011-1016
To study the clinical effect of oral sirolimus in the treatment of children with blue rubber bleb nevus syndrome (BRBNS) in the gastrointestinal tract, a retrospective analysis was performed on the clinical data and follow-up results of two children with BRBNS treated by sirolimus. The two children with BRBNS had gastrointestinal bleeding and anemia and were treated with sirolimus at a dose of 1 mg/day as part of treatment. The plasma concentration of the drug was maintained between 2.5-12.0 ng/mL. The children showed disappearance of gastrointestinal bleeding and improvements in anemia and coagulation function, and blood transfusion could be stopped during treatment, with no obvious adverse drug reactions. PubMed, Wanfang Data, and CNKI were searched for related articles on sirolimus in the treatment of BRBNS. A total of 26 cases of children with BRBNS, aged 0-18 years, were obtained. With the addition of the 2 cases in this study, sirolimus treatment achieved a satisfactory clinical effect in all 28 cases. Sirolimus may be effective and safe in the treatment of children with BRBNS, and further prospective studies are needed to evaluate the long-term efficacy of this drug.
Adolescent
;
Child
;
Child, Preschool
;
Gastrointestinal Neoplasms
;
drug therapy
;
Humans
;
Infant
;
Infant, Newborn
;
Nevus, Blue
;
drug therapy
;
Prospective Studies
;
Retrospective Studies
;
Sirolimus
;
therapeutic use
;
Skin Neoplasms
;
drug therapy
9.Chlorophyll derivatives: a new photosensitizer for photodynamic therapy of cancer in mice.
Yong Joon PARK ; Won Young LEE ; Bo Sup HAHN ; Man Jung HAN ; Woo Ick YANG ; Byung Soo KIM
Yonsei Medical Journal 1989;30(3):212-218
The in vivo photosensitizing efficacy of chlorophyll derivatives(CpD), which had been developed as a new photosensitizer, was compared with that of hematoporphyrin derivatives (HpD). A murine tumor model implanted subcutaneously with S-180 cells on the abdomen was used. The CpD or HpD was administered by intratumoral injection, and light of appropriate wavelength was irradiated on the tumor areas for 10 minutes at 1h and 24h or 24h and 48h after the injection of photosensitizer. When CpD was injected, the early irradiation group (1h and 24h) showed a 100% tumor cure rate; however, the late irradiation group (24h and 48h) showed a 60% tumor cure rate (p less than 0.01). This showed that the early irradiation with light after injection of CpD was an important factor for obtaining better results. With HpD, there was no difference in tumor cure rate between early (1h and 24h, 80%) and late irradiation (24h and 48h, 80%) groups. Thus, in early irradiation groups, the tumor cure rate using CpD (100%) was superior to that of HpD (80%) (p less than 0.05). However, in late irradiation groups, the tumor cure rate using CpD (60%) was inferior to that of HpD (80%), but this difference was not statistically significant (p greater than 0.1). Pathologic sections of these tumors were made before treatment and 48h and 3 weeks after treatment. These showed geographic necrosis at 48h after treatment and no viable tumor tissue at 3 weeks after treatment. Our results showed that CpD was as effective as HpD as a photosensitizer for in vivo photodynamic therapy.
Abdomen
;
Animal
;
Chlorophyll/*analogs and derivatives
;
Mice
;
Mice, Inbred ICR
;
Photochemotherapy/*methods
;
Sarcoma, Experimental/*drug therapy
;
Skin Neoplasms/*drug therapy
10.Chlorophyll derivatives: a new photosensitizer for photodynamic therapy of cancer in mice.
Yong Joon PARK ; Won Young LEE ; Bo Sup HAHN ; Man Jung HAN ; Woo Ick YANG ; Byung Soo KIM
Yonsei Medical Journal 1989;30(3):212-218
The in vivo photosensitizing efficacy of chlorophyll derivatives(CpD), which had been developed as a new photosensitizer, was compared with that of hematoporphyrin derivatives (HpD). A murine tumor model implanted subcutaneously with S-180 cells on the abdomen was used. The CpD or HpD was administered by intratumoral injection, and light of appropriate wavelength was irradiated on the tumor areas for 10 minutes at 1h and 24h or 24h and 48h after the injection of photosensitizer. When CpD was injected, the early irradiation group (1h and 24h) showed a 100% tumor cure rate; however, the late irradiation group (24h and 48h) showed a 60% tumor cure rate (p less than 0.01). This showed that the early irradiation with light after injection of CpD was an important factor for obtaining better results. With HpD, there was no difference in tumor cure rate between early (1h and 24h, 80%) and late irradiation (24h and 48h, 80%) groups. Thus, in early irradiation groups, the tumor cure rate using CpD (100%) was superior to that of HpD (80%) (p less than 0.05). However, in late irradiation groups, the tumor cure rate using CpD (60%) was inferior to that of HpD (80%), but this difference was not statistically significant (p greater than 0.1). Pathologic sections of these tumors were made before treatment and 48h and 3 weeks after treatment. These showed geographic necrosis at 48h after treatment and no viable tumor tissue at 3 weeks after treatment. Our results showed that CpD was as effective as HpD as a photosensitizer for in vivo photodynamic therapy.
Abdomen
;
Animal
;
Chlorophyll/*analogs and derivatives
;
Mice
;
Mice, Inbred ICR
;
Photochemotherapy/*methods
;
Sarcoma, Experimental/*drug therapy
;
Skin Neoplasms/*drug therapy